Prelude Therapeutics PRLD
NASDAQ PRLD
$3.93 -0.03 (-0.76%)
As of: Sep 30, 2026 · 3:00 PM EDT

Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2026)

Updated

Prelude Therapeutics (PRLD) recorded Current Deferred Revenue of $25.25 million in Q2 2026, down 18.4% from the prior quarter.

Analysis

Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2026) Analysis & Trends

At the end of FY2025, Prelude Therapeutics reported Current Deferred Revenue of $33.73 million.

  • The Q2 2026 figure is the lowest quarterly Current Deferred Revenue since Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Prelude Therapeutics 316.02 Mn -281.28 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 25.25 Mn
Mar 31, 2026 30.95 Mn
Dec 31, 2025 33.73 Mn
Jun 30, 2024 3.00 Mn
API Access

Prelude Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=PRLD&period=max&api_key=YOUR_API_KEY